Cardio Diagnostics Holdings

Executive Summary

Cardio Diagnostics Holdings (NASDAQ: CDIO) is a U.S.-based biotechnology company pioneering AI-driven epigenetic and genetic tests for cardiovascular disease. Its lead products, Epi+Gen CHD™ and PrecisionCHD™, assess coronary heart disease risk and aid in diagnosing obstructive coronary heart disease, respectively. By integrating artificial intelligence with epigenetic and genetic analysis, the company aims to provide clinicians with actionable insights for prevention and management of cardiovascular conditions. Since its founding in 2020 and public listing, Cardio Diagnostics has focused on regulatory clearances and commercial partnerships to embed its tests into healthcare systems.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance or CE mark for PrecisionCHD™40% success
• TBDStrategic commercial partnership with a major healthcare provider or diagnostic lab50% success
• Q3 2026Publication of clinical validation study for Epi+Gen CHD™ in a peer-reviewed journal60% success